<!DOCTYPE html>
<html>
<head>
    <meta charset="UTF-8">
    <title>Extracted Document</title>
    <style>
        body { font-family: Arial, sans-serif; max-width: 900px; margin: 0 auto; padding: 20px; }
        h1, h2, h3 { color: #333; }
        .page { margin-bottom: 50px; border-bottom: 2px solid #ccc; padding-bottom: 30px; }
        .title { font-size: 1.3em; font-weight: bold; margin: 20px 0; }
        .text { margin: 15px 0; line-height: 1.6; }
        .figure { margin: 20px 0; text-align: center; }
        .figure img { max-width: 100%; height: auto; border: 1px solid #ddd; }
        .figure-caption { font-style: italic; color: #666; margin-top: 10px; }
        .metadata { background: #f5f5f5; padding: 15px; margin-top: 30px; }
    </style>
</head>
<body>

<h1>Extracted Document</h1>
<p><strong>Source:</strong> data/marketing_slide/FlublokOnePage.pdf</p>
<p><strong>Total Pages:</strong> 1</p>
<hr>
<div class="page">
<h2>Page 1</h2>
<div class="text">Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of Flublok. Please see additional Important Safety Information throughout. Before administration, please see full Prescribing Information here.</div>
<div class="figure">
<img src="figures/figure_p1_482d1ad0.png" alt="[FIGURE 3 - See figure_p1_482d1ad0.png]" style="max-width: 800px;">
<div class="figure-caption">[FIGURE 3 - See figure_p1_482d1ad0.png]</div>
</div>
<div class="text">s, which may potentially protect against grams (mcg) of HA per strain vs 15 mcg o</div>
<div class="text">as evaluated in the pivotal trial against Fluarix (quad rival ent sare manufactured using the same process and have over lapp g a novel production platform in which recombinant HA is exp sing BEVS have been shown to induce significantly higher leve</div>
<div class="figure">
<img src="figures/figure_p1_1ac082de.png" alt="[FIGURE 6 - See figure_p1_1ac082de.png]" style="max-width: 800px;">
<div class="figure-caption">[FIGURE 6 - See figure_p1_1ac082de.png]</div>
</div>
<div class="text">accine.1-3</div>
<div class="text">he efcacy of Flublok (quad rival ent is relevant to Flublok (trivalent) g abaculo virus expression vector system (BEVS). Recombinant ve antibodies against highly conserved regions of HA compared</div>
<div class="text">broader immune resp id i</div>
<div class="text">MAY PROVIDE CROSS-PROTECTION4 Recombinant technology leads to a</div>
<div class="text">g y p yin January 2024, vaccination with a higher dose recombinant flu vaccine may induce amore robust antibody response than egg based standard dose vaccines.</div>
<div class="figure">
<img src="figures/figure_p1_e555aa98.png" alt="[FIGURE 13 - See figure_p1_e555aa98.png]" style="max-width: 800px;">
<div class="figure-caption">[FIGURE 13 - See figure_p1_e555aa98.png]</div>
</div>
<div class="text">Cell and egg based flu vaccines have the potential to develop mutations</div>
<div class="text">AVOIDS MUTATIONS4 Cell- and egg based flu vaccines hav</div>
<div class="text">AN EXACT STRAIN MATCH 4 5 The only recombinant flu vaccine that has known and exact antigen content, Flublok ensures identical antigenic match with WHO3 x THE ANTIGEN1-3 Flublok also contains 3 x the hemagglutinin (HA) antigen content of standard dose flu vaccines, which has been linked to greater immunogen i city 3 x</div>
<div class="text">Flublok COMBINES THE ADVANTAGES OF RECOMBINANT T WITH A HIGHER DOSE 2 4</div>
<div class="text">HNOLOGY</div>
<div class="text">CHNOLOGY</div>
</div>
<div class="metadata">
<h3>Extraction Metadata</h3>
<p>Text blocks: 14</p>
<p>Figures/Tables: 3</p>
</div>

</body>
</html>
